for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

HanmiPharm

128940.KS

Latest Trade

299,500.00KRW

Change

-3,500.00(-1.16%)

Volume

19,307

Today's Range

299,500.00

 - 

304,000.00

52 Week Range

254,901.92

 - 

427,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
303,000.00
Open
303,000.00
Volume
19,307
3M AVG Volume
0.98
Today's High
304,000.00
Today's Low
299,500.00
52 Week High
427,000.00
52 Week Low
254,901.92
Shares Out (MIL)
11.98
Market Cap (MIL)
3,653,680.00
Forward P/E
63.11
Dividend (Yield %)
0.16

Next Event

Q3 2021 Hanmi Pharm Co Ltd Earnings Release

Latest Developments

More

Hanmi Pharm Q3 Operating Loss 32 Billion Won, Swings To Loss From Year Earlier

Merck And Hanmi Pharmaceutical Enter Into Licensing Agreement To Develop Efinopegdutide

Hanmi Pharm Q2 Operating Profit $19.6 Mln Vs $16.8 Mln Profit Year Ago

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About HanmiPharm

Hanmi Pharm Co Ltd is a Korea-based company principally engaged in the manufacturing and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.

Industry

Biotechnology & Drugs

Contact Info

214, Muha-ro, Paltan-myeon

18536

South Korea

+82.31.3505600

http://www.hanmi.co.kr

Executive Leadership

Yeong Suk Song

Chairman

Seong Gi Yim

Chairman

Se Chang Gwon

Co-President, Co-Chief Executive Officer, Executive Director

Jong Su Woo

Co-President, Co-Chief Executive Officer, Executive Director

Jong Yun Yim

Co-President, Executive Director

Key Stats

2.13 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2018

1.0K

2019

1.1K

2020

1.1K

2021(E)

1.1K
EPS (KRW)

2018

2,115.532

2019

4,425.489

2020

997.000

2021(E)

4,800.988
Price To Earnings (TTM)
157.00
Price To Sales (TTM)
3.34
Price To Book (MRQ)
4.79
Price To Cash Flow (TTM)
34.36
Total Debt To Equity (MRQ)
103.91
LT Debt To Equity (MRQ)
38.84
Return on Investment (TTM)
2.57
Return on Equity (TTM)
1.61

Latest News

Latest News

S.Korea's Genexine signs COVID-19 vaccine candidate manufacturing deal with Hanmi

Genexine Inc has signed a manufacturing deal for its COVID-19 vaccine candidate with Hanmi Pharm Co Ltd as it prepares to seek emergency use approval of the shot in South Korea and Indonesia, Genexine said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up